These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18294469)

  • 1. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with cardiorenal anemia syndrome.
    Leszek P; Kruszewski M
    Am Heart J; 2008 Mar; 155(3):e25; author reply e19. PubMed ID: 18294469
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
    Palazzuoli A; Silverberg DS; Iovine F; Calabrò A; Campagna MS; Gallotta M; Nuti R
    Am Heart J; 2007 Oct; 154(4):645.e9-15. PubMed ID: 17892986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
    Palazzuoli A; Silverberg DS; Calabrò A; Spinelli T; Quatrini I; Campagna MS; Franci B; Nuti R
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):462-7. PubMed ID: 19455052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes.
    O'Meara E; Rouleau JL; White M; Roy K; Blondeau L; Ducharme A; Neagoe PE; Sirois MG; Lavoie J; Racine N; Liszkowski M; Madore F; Tardif JC; de Denus S;
    Circ Heart Fail; 2014 Sep; 7(5):773-81. PubMed ID: 25027873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.
    van der Putten K; Jie KE; Emans ME; Verhaar MC; Joles JA; Cramer MJ; Velthuis BK; Meiss L; Kraaijenhagen RJ; Doevendans PA; Braam B; Gaillard CA
    J Nephrol; 2010; 23(4):363-8. PubMed ID: 20383871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in natriuretic peptides following passive containment surgery in heart failure patients with dilated cardiomyopathy.
    Bredin F; Liska J; Franco-Cereceda A
    Interact Cardiovasc Thorac Surg; 2009 Feb; 8(2):191-4. PubMed ID: 19008326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of the isovolumic relaxation time in the emergency diagnosis of new-onset congestive heart failure with preserved left ventricular systolic function in the setting of B-type natriuretic peptide levels in the mid-range.
    Arques S; Roux E; Sbragia P; Pieri B; Gelisse R; Ambrosi P; Luccioni R
    Int J Cardiol; 2008 Mar; 124(3):400-3. PubMed ID: 17395301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-type natriuretic peptide and the stressed heart.
    Nohria A; Givertz MM
    J Am Coll Cardiol; 2006 Feb; 47(4):749-51. PubMed ID: 16487839
    [No Abstract]   [Full Text] [Related]  

  • 11. Surrogate end points in heart failure trials.
    Gheorghiade M; Adams KF; Gattis WA; Teerlink JR; Orlandi C; O'Connor CM
    Am Heart J; 2003 Feb; 145(2 Suppl):S67-70. PubMed ID: 12594457
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients.
    van der Putten K; Jie KE; van den Broek D; Kraaijenhagen RJ; Laarakkers C; Swinkels DW; Braam B; Gaillard CA
    Eur J Heart Fail; 2010 Sep; 12(9):943-50. PubMed ID: 20601671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between B-type natriuretic peptide plasma level and left ventricular function in patients with chronic kidney disease on different type of treatment].
    Rasić S; Hadzovic-Dzuvo A; Rebić D; Dzemidzić J; Bilal F; Mataradzija A
    Acta Med Croatica; 2008; 62 Suppl 1():7-11. PubMed ID: 18578326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natriuretic peptides in heart failure: their role in daily practice.
    Loboz-Grudzień K; Jaroch J
    Cardiol J; 2009; 16(1):1-3. PubMed ID: 19130409
    [No Abstract]   [Full Text] [Related]  

  • 15. Relation of anemia to diastolic heart failure and the effect on outcome.
    Brucks S; Little WC; Chao T; Rideman RL; Upadhya B; Wesley-Farrington D; Sane DC
    Am J Cardiol; 2004 Apr; 93(8):1055-7. PubMed ID: 15081458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiorenal anemia syndrome (review)].
    Minasyan A
    Georgian Med News; 2012 Dec; (213):17-21. PubMed ID: 23293227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
    Silverberg DS; Wexler D; Blum M; Tchebiner J; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Zubkov A; Steinbruch S; Iaina A
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S37-45. PubMed ID: 12227725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and chronic heart failure implications and treatment options.
    Anand IS
    J Am Coll Cardiol; 2008 Aug; 52(7):501-11. PubMed ID: 18687241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic partial unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in failing rat hearts.
    Wang J; Tsukashita M; Nishina T; Marui A; Yoshikawa E; Muranaka H; Matsuoka S; Ikeda T
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):465-70. PubMed ID: 19185171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The cardiorenal anemia syndrome and treatment with EPO].
    Karle H; Hansen NE
    Ugeskr Laeger; 2006 Aug; 168(33):2686. PubMed ID: 16953546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.